RecruitingNCT02622581

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Sponsor

AIO-Studien-gGmbH

Enrollment

12,400 participants

Start Date

Dec 1, 2015

Study Type

OBSERVATIONAL

Conditions

Non-small Cell Lung Cancer Metastatic Non-small Cell Lung Cancer Stage II Metastatic Non-small Cell Lung Cancer (NSCLC)

Summary

Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is a large research platform tracking patients with lung cancer — including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) at all stages — to understand how genetic (molecular) testing of the tumor influences treatment choices and long-term outcomes. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with non-small cell lung cancer (NSCLC) at any stage, or with small cell lung cancer (SCLC) - You are within four weeks of starting your first cancer treatment (including surgery, radiation, chemotherapy, or best supportive care) - You are able to understand and sign a consent form - For the main project: you have stage IV NSCLC, or stage IIIB/C if surgery and combined chemo-radiation are not options for you **You may NOT be eligible if...** - You do not have a confirmed diagnosis of lung cancer - You are unable or unwilling to sign a consent form - You have missed the four-week window after starting your first treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERdata collection

Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.